Brokerages Set Edwards Lifesciences Co. (NYSE:EW) Target Price at $79.19

Edwards Lifesciences Co. (NYSE:EW) has been given an average rating of “Hold” by the twenty-six analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $79.19.

A number of research analysts recently issued reports on EW shares. JPMorgan Chase & Co. lifted their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Wolfe Research downgraded Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective for the company. in a report on Thursday, January 16th. Citigroup boosted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. Finally, Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th.

Edwards Lifesciences Stock Up 1.1 %

NYSE EW opened at $72.10 on Monday. The business has a fifty day moving average price of $72.49 and a 200 day moving average price of $69.52. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $42.52 billion, a P/E ratio of 10.40, a P/E/G ratio of 3.72 and a beta of 1.11. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,000 shares of company stock worth $547,430 over the last three months. 1.27% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently added to or reduced their stakes in the business. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $30,000. FSA Wealth Management LLC purchased a new stake in Edwards Lifesciences in the third quarter valued at approximately $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences during the third quarter worth approximately $32,000. Avior Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $46,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.